Agreed,
NP missed his self-imposed deadline. The moral here is that one shouldn’t set deadlines over things that one does not control completely. I give it to you: by now Nader should know that and be more careful about what he says.
The reason(s) for the delay are likely out of NP’s control. What are they being unknown, I believe that, as you say, we are owned an explanation. Also, I understand that sometimes providing this is difficult as it might need to disclose something that cannot be disclosed at this stage. Fair enough, however the owners of the company (we) deserve at least an apology.
I personally like Nader’s interviews, I find them useful as I listen carefully, watch his body language, and, learn a lot on what is happening (or not) helping me in my decision-making process. Also, I find it makes the company more democratic in the sense that here is a good communication with the directives. This is not the case very often with other companies.
I have been accumulating stock for long time now (longer than I would like to admit) as a result of my DD and the information he has shared. Of course, one can argue that perhaps he has been lying all along and deserves an academy Oscar. I have asked myself that, however, after reading several papers on the subject and listening also to the doctors that are at the front-line of research I have, long time ago, concluded that this is for real, consequently I have invested heavily in CYDY. Besides, NP is a very religious man (wrote a book in this general area) and his religion does not treat kindly those who lie (religion being a touchy subject but I think is important in this context.)
So, I am waiting for an explanation, if this is not possible an apology and, in the future, more interviews without deadlines (BTW, I give him a pass as the command of English is not perfect, therefore subtlety when emitting some concepts might be more difficult for him, however when one is the CEO of a ccompany careful preparation of public comments is a must).
We have a bright future ahead, several important catalyzers are coming very soon and there is only one way for the SP: up. I read some of you saying that could not sleep due to the excitement of the news coming, I think there is good reason for this excitement and lack of sleep.
For those looking for something to read this weekend ,an interesting article in Cancer Research , “ Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology ”, it mentions:
https://cancerres.aacrjournals.org/content/79/19/4801
“ Recent studies suggest important cross-talk between CCR5 signaling and immune checkpoint function. Because CCR5 on Tregs serves as the coreceptor for human immunodeficiency virus (HIV) entry, CCR5-targeted therapeutics used in HIV, [small molecules (maraviroc and vicriviroc) and a humanized mAb ( leronlimab )], are now being repositioned in clinical trials as cancer therapeutics. As CCR5 is expressed on a broad array of tumors, the opportunity for therapeutic repositioning and the rationale for combination therapy approaches are reviewed herein. ”
Also: “ CCR5 is overexpressed in breast cancer, gastric adenocarcinoma, prostate cancer, colorectal carcinoma, melanoma, Hodgkin lymphoma, head and neck cancer, gastric cancer, esophageal cancer, pancreatic cancer, acute lymphocytic leukemia, and other tumors. In analysis of >2,200 patients with breast cancer, >50% of patient's tumors were CCR5+ and >95% of triple-negative breast cancer (TNBC) were CCR5+ . Higher cytoplasmic CCR5 staining correlated with poor prognosis .. ”
It contains more information on the blocked metastasis of human breast cancer xenografts in immunodeficient mice (related to the slide in CYDY presentation).
NP missed his self-imposed deadline. The moral here is that one shouldn’t set deadlines over things that one does not control completely. I give it to you: by now Nader should know that and be more careful about what he says.
The reason(s) for the delay are likely out of NP’s control. What are they being unknown, I believe that, as you say, we are owned an explanation. Also, I understand that sometimes providing this is difficult as it might need to disclose something that cannot be disclosed at this stage. Fair enough, however the owners of the company (we) deserve at least an apology.
I personally like Nader’s interviews, I find them useful as I listen carefully, watch his body language, and, learn a lot on what is happening (or not) helping me in my decision-making process. Also, I find it makes the company more democratic in the sense that here is a good communication with the directives. This is not the case very often with other companies.
I have been accumulating stock for long time now (longer than I would like to admit) as a result of my DD and the information he has shared. Of course, one can argue that perhaps he has been lying all along and deserves an academy Oscar. I have asked myself that, however, after reading several papers on the subject and listening also to the doctors that are at the front-line of research I have, long time ago, concluded that this is for real, consequently I have invested heavily in CYDY. Besides, NP is a very religious man (wrote a book in this general area) and his religion does not treat kindly those who lie (religion being a touchy subject but I think is important in this context.)
So, I am waiting for an explanation, if this is not possible an apology and, in the future, more interviews without deadlines (BTW, I give him a pass as the command of English is not perfect, therefore subtlety when emitting some concepts might be more difficult for him, however when one is the CEO of a ccompany careful preparation of public comments is a must).
We have a bright future ahead, several important catalyzers are coming very soon and there is only one way for the SP: up. I read some of you saying that could not sleep due to the excitement of the news coming, I think there is good reason for this excitement and lack of sleep.
For those looking for something to read this weekend ,an interesting article in Cancer Research , “ Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology ”, it mentions:
https://cancerres.aacrjournals.org/content/79/19/4801
“ Recent studies suggest important cross-talk between CCR5 signaling and immune checkpoint function. Because CCR5 on Tregs serves as the coreceptor for human immunodeficiency virus (HIV) entry, CCR5-targeted therapeutics used in HIV, [small molecules (maraviroc and vicriviroc) and a humanized mAb ( leronlimab )], are now being repositioned in clinical trials as cancer therapeutics. As CCR5 is expressed on a broad array of tumors, the opportunity for therapeutic repositioning and the rationale for combination therapy approaches are reviewed herein. ”
Also: “ CCR5 is overexpressed in breast cancer, gastric adenocarcinoma, prostate cancer, colorectal carcinoma, melanoma, Hodgkin lymphoma, head and neck cancer, gastric cancer, esophageal cancer, pancreatic cancer, acute lymphocytic leukemia, and other tumors. In analysis of >2,200 patients with breast cancer, >50% of patient's tumors were CCR5+ and >95% of triple-negative breast cancer (TNBC) were CCR5+ . Higher cytoplasmic CCR5 staining correlated with poor prognosis .. ”
It contains more information on the blocked metastasis of human breast cancer xenografts in immunodeficient mice (related to the slide in CYDY presentation).
6
